Virus neutralization remains the gold standard for determining antibody efficacy. Therefore, a high-throughput assay to measure SARS-CoV-2 neutralizing antibodies is urgently needed for COVID-19 serodiagnosis, convalescent plasma therapy, and vaccine development. Here, we report on a fluorescence-based SARS-CoV-2 neutralization assay that detects SARS-CoV-2 neutralizing antibodies in COVID-19 patient specimens and yields comparable results to plaque reduction neutralizing assay, the gold standard of serological testing. The fluorescence-based neutralization assay is specific to measure COVID-19 neutralizing antibodies without cross reacting with patient specimens with other viral, bacterial, or parasitic infections. Collectively, our approach offers a rapid platform that can be scaled to screen people for antibody protection from COVID-19, a key parameter necessary to safely reopen local communities. Neutralizing antibody titers in SARS-CoV-2 infected or vaccinated people are an important measure for vaccine development and public health decision-making. Here, the authors develop a fluorescence based SARS-CoV-2 assay to determine neutralizing antibody titers in COVID-19 patient sera in a high throughput set-up.
【저자키워드】 SARS-CoV-2, Infectious-disease diagnostics, 【초록키워드】 COVID-19, neutralizing antibody, public health, Efficacy, Vaccine development, antibody, neutralization, Local, infections, Convalescent plasma therapy, Serological testing, Neutralization assay, sera, Patient, Antibody titer, Neutralizing, cross, platform, SARS-CoV-2 neutralization, SARS-CoV-2 neutralizing antibody, Neutralizing antibody titer, Bacterial, COVID-19 patient, reduction, gold standard, specimen, offer, parameter, approach, detect, develop, determine, comparable, scaled, 【제목키워드】 neutralizing antibody, Vaccine, COVID-19 diagnosis,